Oragenics Files 2025 Annual Report and Updates Shareholders on Clinical and Financial Progress

Oragenics Inc. (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2025, alongside a shareholder update detailing operational, clinical, and financial progress. The company reported achieving several key milestones throughout 2025, including the restoration of its compliance with NYSE American listing standards, which is crucial for maintaining its public market presence and investor confidence. This regulatory achievement was complemented by a significant capital raise of $16.5 million, providing essential funding to advance the company's research and development initiatives.

A major operational shift highlighted in the update was the transition of drug manufacturing to a U.S.-based facility. This strategic move is designed to streamline the supply chain and enhance control over the production of its lead candidate, ONP-002, which is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. The advancement of the ONP-002 program represents the core of Oragenics' clinical strategy, leveraging its proprietary intranasal delivery technology to target therapeutics directly to the brain.

The company also outlined its early 2026 progress, focusing on the initiation of a Phase IIa clinical trial for ONP-002 in Australia. This international trial initiation is a critical step in the drug's development pathway, with U.S. Phase 2b trials planned to follow, aiming to address a significant unmet medical need in neurological care. Oragenics' strategic priorities for the coming period emphasize accelerating patient enrollment, advancing U.S. regulatory discussions with the Food and Drug Administration, and expanding its central nervous system pipeline. The pipeline has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, as detailed in the company's corporate information available at https://oragenics.com.

The filing of the Form 10-K provides investors with a comprehensive view of the company's financial health and strategic direction following a year of substantial corporate and clinical groundwork. The operational update underscores Oragenics' transition from a period of financial and regulatory stabilization to one focused on clinical execution and pipeline growth. The progress in Australia and the planned U.S. regulatory activities are pivotal for validating the intranasal platform's efficacy and safety, which could have broad implications for treating various brain disorders. For ongoing news and updates relating to OGEN, information is available in the company’s newsroom at https://ibn.fm/OGEN. The convergence of restored compliance, strengthened finances, and clinical momentum positions Oragenics to potentially deliver innovative therapies in the competitive neurology space.